» Articles » PMID: 35700669

Prevalence, Incidence, and Season Distribution of MOG Antibody-associated Disease in the Province of Verona, Italy

Overview
Specialty Neurology
Date 2022 Jun 14
PMID 35700669
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system whose epidemiological features are still unclear. We report current prevalence and incidence rates of MOGAD in the population of Verona province, Italy, and the seasonal distribution of disease onset.

Methods: MOGAD patients residing in Verona province were included through the consultation of a database from our Neuropathology Laboratory. Provincial prevalence was determined on 2021/1/1 (resident population: 922,291 people) and incidence rates between 2016/1/1 and 2021/1/1 were calculated from all cases, divided by the total number of person-years at risk. We also examined the distribution of attacks by month and season.

Results: We included 23 prevalent MOGAD cases (13 females), with a median age at onset of 36 years (range 5-69). Prevalence rate was 2.5/100,000 (95% CI 1.7-3.7). 22 incident cases were collected, with an incidence rate of 4.8/million person-years (95% CI 3.1-7.2). Among the 23 prevalent patients, disease onset was more frequent in December (4 cases), February, May, and September (3 cases/month), with a global autumn-winter predominance (September-February) of 15 cases (65%), irrespective of the clinical manifestation.

Conclusions: This is the first study on an Italian population to report MOGAD prevalence and incidence rates; they are higher than the estimates for aquaporin-4-seropositive neuromyelitis optica spectrum disorder in the Caucasian population, but far lower than Multiple Sclerosis. An autumn-winter predominance of disease onset is suggested, and it could be related to environmental factors that should be ascertained, although validation in larger cohorts is mandatory.

Citing Articles

MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique.

Cacciaguerra L, Sechi E, Komla-Soukha I, Chen J, Smith C, Jenkins S J Neurol. 2025; 272(2):118.

PMID: 39812824 DOI: 10.1007/s00415-024-12861-9.


Aggressive Course of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): An Illustration of Two Cases and Review of Literature.

Frade H, Elnaeem A, Banerjee P, Sharma T, Wu L, Dabi A Cureus. 2024; 16(9):e68563.

PMID: 39364495 PMC: 11449492. DOI: 10.7759/cureus.68563.


Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide.

Hor J, Fujihara K Front Neurol. 2023; 14:1260358.

PMID: 37789888 PMC: 10542411. DOI: 10.3389/fneur.2023.1260358.


Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis.

Vlad B, Reichen I, Neidhart S, Hilty M, Lekaditi D, Heuer C Front Immunol. 2023; 14:1237149.

PMID: 37744325 PMC: 10516557. DOI: 10.3389/fimmu.2023.1237149.